Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Waldenstrom Macroglobulinemia 1Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Hematologic Diseases 1B-cell Malignancies 1

Interventions

zanubrutinib 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × B-cell Malignancies × zanubrutinib × Clear all
NCT04170283 2025-10-21

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

BeOne Medicines

Phase 3 Active not recruiting
955 enrolled
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡